F. Boomsma et al., PLASMA SEMICARBAZIDE-SENSITIVE AMINE OXIDASE IS ELEVATED IN PATIENTS WITH CONGESTIVE-HEART-FAILURE, Cardiovascular Research, 33(2), 1997, pp. 387-391
Objective: Semicarbazide-sensitive amine oxidase (SSAO) is present in
various mammalian tissues, especially in vascular smooth muscle cells,
but also in plasma. The enzyme has been suggested to play a role in v
ascular endothelial damage through conversion of amines into cytotoxic
aldehydes, ammonia and hydrogen peroxide. Endothelial dysfunction is
present in diabetes mellitus (DM) and congestive heart failure (CHF).
Elevated plasma SSAO activities have been reported in patients with DM
, bur no data on patients with CHF are as yet available. Methods and R
esults: Plasma SSAO was measured in 271 patients with CHF and compared
to values in 77 controls. SSAO was found to be elevated in patients w
ith CHF compared to controls (589 +/- 252 vs. 355 +/- 114 mU/l; P < 0.
0001). Plasma SSAO was higher in NYHA class III/IV than in class III (
662 +/- 288 vs. 555 +/- 226 mU/l; P = 0.004) and also higher in patien
ts with concomitant DM than in those without (706 +/- 248 vs. 557 +/-
245 mU/l; P < 0.0001). Plasma SSAO correlated with plasma atrial natri
uretic peptide (r = 0.421 P < 0.0001), with plasma norepinephrine (r =
0.27: P < 0.0001) and with left ventricular ejection fraction (r = -0
.13; P = 0.0162). Multiple regression analysis showed atrial natriuret
ic peptide, norepinephrine, DM and cardiothoracic ratio to be the main
determinants of plasma SSAO. Conclusion: The finding of elevated plas
ma SSAO in CHF, increasing with severity of the disease and with the c
oncomitant presence of DM, supports the suggestion that SSAO may be in
volved in the pathogenesis of vascular endothelial damage. Plasma SSAO
may be a useful parameter in assessing severity of CHF and in prognos
tic evaluation. Pharmacologic manipulation of SSAO activity might be a
n interesting new concept for prevention of vascular endothelial damag
e in various vascular disease entities.